白蛋白结合型紫杉醇周疗联合曲妥珠单抗和帕妥珠单抗对比多西他赛、卡铂、曲妥珠单抗和帕妥珠单抗在HER2阳性早期乳腺癌患者中的降阶梯新辅助治疗(HELEN-006):一项多中心、随机、3期试验
HELEN-006是一项在中国六家医院开展的多中心、随机、3期试验,比较每周白蛋白结合型紫杉醇联合曲妥珠单抗和帕妥珠单抗与多西他赛+卡铂联合双靶向新辅助治疗HER2阳性早期乳腺癌的疗效。全分析集669例中,白蛋白结合型紫杉醇组病理完全缓解率为66.3%,对照组为57.6%(合并OR 1.54,95%CI 1.10-2.14;分层P=0.011)。白蛋白结合型紫杉醇组3-4级不良事件发生率为30%,对照组为38%。
要点
- 白蛋白结合型紫杉醇组病理完全缓解率66.3%,多西他赛+卡铂组57.6%,合并OR 1.54(95%CI 1.10-2.14),分层P=0.011。
- 白蛋白结合型紫杉醇组3-4级不良事件30%,多西他赛+卡铂组38%;3-4级恶心7% vs 23%,腹泻8% vs 16%,神经病变13% vs 2%。
- 两组均未报告治疗相关死亡;严重药物相关不良事件分别为1%和2%。
核心结论
- 这些发现可能提示白蛋白结合型紫杉醇联合曲妥珠单抗和帕妥珠单抗在HER2阳性早期乳腺癌新辅助治疗中相较于标准方案具有潜在优势,提示这一新联合方案可能为该患者群体建立新的新辅助治疗标准。
研究设计与样本
- HELEN-006是一项在中国六家医院开展的多中心、随机、3期试验。
- 研究纳入18-70岁、未经治疗、组织学确诊的II-III期浸润性HER2阳性乳腺癌、ECOG体能状态评分为0或1的患者。
- 采用交互式应答系统按1:1随机分组,区组大小为四,按肿瘤分期、淋巴结状态和激素受体状态分层。
- 白蛋白结合型紫杉醇组接受静脉白蛋白结合型紫杉醇125 mg/m2(第1、8、15天),每3周为一周期,共6周期;对照组接受静脉多西他赛75 mg/m2(第1天)联合静脉卡铂(浓度-时间曲线下面积6 mg/mL per min,第1天),每3周为一周期,共6周期。
- 两组均同时接受静脉曲妥珠单抗(初始负荷剂量8 mg/kg,维持剂量6 mg/kg,第1天)和静脉帕妥珠单抗(负荷剂量840 mg,维持剂量420 mg,第1天)。
主要发现
- 2020年9月20日至2023年3月1日期间,筛查789例患者,随机分配689例(白蛋白结合型紫杉醇组343例,多西他赛+卡铂组346例);所有689例均为亚洲女性。
- 669例患者至少接受一剂研究治疗并纳入全分析集(白蛋白结合型紫杉醇组332例,多西他赛+卡铂组337例);中位年龄50岁(IQR 43-55),中位随访时间26个月(IQR 19-32)。
- 白蛋白结合型紫杉醇组220例(66.3% [95% CI 61.2-71.4])达到病理完全缓解,多西他赛+卡铂组194例(57.6% [52.3-62.9])(合并OR 1.54 [95% CI 1.10-2.14];分层P=0.011)。
- 白蛋白结合型紫杉醇组100例(30%)和多西他赛+卡铂组128例(38%)发生3-4级不良事件。
- 最常见的3-4级不良事件为恶心(白蛋白结合型紫杉醇组22例[7%] vs 多西他赛+卡铂组76例[23%])、腹泻(25例[8%] vs 55例[16%])和神经病变(43例[13%] vs 8例[2%]);严重药物相关不良事件分别为3例(1%)和5例(2%);两组均未报告治疗相关死亡。
关键数值与推荐
- 主要终点病理完全缓解(ypT0/is ypN0)在全分析集(改良意向治疗)中分析。
- 白蛋白结合型紫杉醇组病理完全缓解率66.3%(95% CI 61.2-71.4),多西他赛+卡铂组57.6%(52.3-62.9),合并OR 1.54(95% CI 1.10-2.14),分层P=0.011。
- 3-4级不良事件:白蛋白结合型紫杉醇组30%,多西他赛+卡铂组38%。
- 3-4级恶心:白蛋白结合型紫杉醇组7% vs 多西他赛+卡铂组23%;腹泻:8% vs 16%;神经病变:13% vs 2%。
- 严重药物相关不良事件:白蛋白结合型紫杉醇组1% vs 多西他赛+卡铂组2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A previous phase 2 trial showed promising outcomes for patients with HER2-positive early-stage breast cancer using neoadjuvant de-escalation chemotherapy with paclitaxel, trastuzumab, and pertuzumab. We aimed to evaluate the efficacy of weekly nab-paclitaxel compared with the standard regimen of docetaxel plus carboplatin, both with trastuzumab and pertuzumab, as neoadjuvant therapies for patients with HER2-positive breast cancer. METHODS: HELEN-006 was a multicentre, randomised, phase 3 trial done at six hospitals in China. We enrolled patients aged 18-70 years with untreated, histologically confirmed stage II-III invasive HER2-positive breast cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1. Using an interactive response system, patients were randomly assigned (1:1) under a permuted block randomisation scheme (block size of four), stratified by tumour stage, nodal status, and hormone receptor status. Patients received either intravenous nab-paclitaxel (125 mg/m2 on days 1, 8, and 15) for six 3-week cycles, or intravenous docetaxel (75 mg/m2 on day 1) plus intravenous carboplatin (area under the concentration-time curve 6 mg/mL per min on day 1) for six 3-week cycles. Both groups also received concurrent intravenous trastuzumab, with an initial loading dose of 8 mg/kg and a maintenance dose of 6 mg/kg on day 1, as well as intravenous pertuzumab with a loading dose of 840 mg and a maintenance dose of 420 mg on day 1. This report is the final analysis of the primary endpoint, pathological complete response (ypT0/is ypN0), analysed in all patients who started treatment (modified intention to treat). The trial is registered with ClinicalTrials.gov, NCT04547907, and follow-up of the adjuvant phase is ongoing. FINDINGS: Between Sept 20, 2020, and March 1, 2023, 789 patients were screened for eligibility, 689 of whom were randomly assigned (343 to the nab-paclitaxel group and 346 to the docetaxel plus carboplatin group). All 689 patients were Asian women. 669 patients received at least one dose of the study treatment and were included in the full analysis set (332 in the nab-paclitaxel group and 337 in the docetaxel plus carboplatin group). Median age of the patients was 50 years (IQR 43-55). Median follow-up time was 26 months (IQR 19-32). 220 (66·3% [95% CI 61·2-71·4]) patients in the nab-paclitaxel group had a pathological complete response, compared with 194 (57·6% [52·3-62·9]) in the docetaxel plus carboplatin group (combined odds ratio 1·54 [95% CI 1·10-2·14]; stratified p=0·011). 100 (30%) patients in the nab-paclitaxel group and 128 (38%) in the docetaxel plus carboplatin group had grade 3-4 adverse events. The most common grade 3-4 adverse events were nausea (22 [7%] in the nab-paclitaxel group vs 76 [23%] in the docetaxel plus carboplatin group), diarrhoea (25 [8%] vs 55 [16%]), and neuropathy (43 [13%] vs eight [2%]). Serious drug-related adverse events were reported in three (1%) patients in the nab-paclitaxel group and five (2%) in the docetaxel plus carboplatin group. No treatment-related deaths were reported in either group. INTERPRETATION: These findings might suggest a potential advantage of nab-paclitaxel combined with trastuzumab and pertuzumab compared with the standard regimen in neoadjuvant therapy for patients with HER2-positive early breast cancer, suggesting that this new combination might establish a new standard for neoadjuvant treatment in this patient population. FUNDING: National Natural Science Foundation of China, and Science and Technology Research Projects of Henan Province, China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Chen XC, Jiao DC, Qiao JH, et al. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2024. PMID: 39612919. doi:10.1016/S1470-2045(24)00581-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。